PharmaEssentia Corporation received positive opinions from the Data and Safety Monitoring Board (DSMB) of the phase III clinical trial of Ropeginterferon alfa-2b (P1101) for the treatment of essential thrombocythemia (ET). Based on the current data, DSMB confirmed the safety of the study and recommended continuing the study according to the protocol. Upcoming development plan: To continue the phase III clinical trial of Ropeginterferon alfa-2b for the treatment of essential thrombocythemia.

Estimated date of completion: Subject enrollment has reached 90% so far and is expected to be completed as soon as possible. Ropeginterferon alfa-2b has been approved to treat adult patients with PV in the European Union, Taiwan, Switzerland, Israel, South Korea, and the United States. New drug development requires long process, vast investments and with no guarantee in success which may pose investment risks.

The investors are advised to exercise caution and conduct thorough evaluation. New drug name or code:Ropeginterferon alfa-2b(P1101. Date of occurrence of the event: December 30, 2022.